KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Gross Margin (2018 - 2025)

Rigel Pharmaceuticals has reported Gross Margin over the past 8 years, most recently at 91.47% for Q4 2025.

  • For Q4 2025, Gross Margin rose 152.0% year-over-year to 91.47%; the TTM value through Dec 2025 reached 93.33%, up 373.0%, while the annual FY2025 figure was 93.33%, 373.0% up from the prior year.
  • Gross Margin for Q4 2025 was 91.47% at Rigel Pharmaceuticals, down from 93.16% in the prior quarter.
  • Over five years, Gross Margin peaked at 99.61% in Q1 2021 and troughed at 85.49% in Q3 2024.
  • A 5-year average of 95.01% and a median of 95.79% in 2025 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: tumbled -1000bps in 2024 and later surged 767bps in 2025.
  • Year by year, Gross Margin stood at 97.61% in 2021, then grew by 2bps to 99.33% in 2022, then dropped by -10bps to 89.41% in 2023, then increased by 1bps to 89.95% in 2024, then rose by 2bps to 91.47% in 2025.
  • Business Quant data shows Gross Margin for RIGL at 91.47% in Q4 2025, 93.16% in Q3 2025, and 95.57% in Q2 2025.